March 19, 2010 — Simvastatin (Zocor, Merck/Schering-Plough Pharmaceuticals), used at the highest approved dose of 80 mg, is associated with an increased risk for myopathy, including rhabdomyolysis, ...

Rockville, MD - Simvastatin (Zocor, Merck/Schering-Plough), used at the highest approved dose of 80 mg, is associated with an increased risk of myopathy, including rhabdomyolysis, according to the US ...

The fact that 80 daily milligrams of simvastatin (brand name Zocor) can cause serious muscle damage has been known for years. So why did it take the Food and Drug Administration so long to tell ...

New FDA Approved Labeling For VYTORIN(R) (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease FDA ...

Exclusive: The UK medicines regulator is set to run into conflict with NICE guidance by advising there is ‘no significant benefit' in using doses of simvastatin over 20 mg. A spokesperson from the ...

WHITEHOUSE STATION and KENILWORTH, N.J., July 23, 2004 — Merck/Schering-Plough Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved VYTORIN TM (ezetimibe/simvastatin ...

STOCKHOLM—New results suggest that combination therapy with ezetimibe/simvastatin, when prescribed at the recommended starting and next higher doses, is more likely to improve lipids than atorvastatin ...

The FDA rejected a new indication for Merck's Vytorin and Zetia (ezetimibe plus simvastatin and ezetimibe alone) in chronic kidney disease patients. As a consolation prize, however, the agency ...

Patients treated with a new investigational combination pill showed significant improvements in cholesterol, triglycerides and other key lipids that lead to heart disease. Simcor combines prescription ...

FDA Approves New Labeling for VYTORIN to Include Data From SHARP Showing That VYTORIN Effectively Lowered LDL Cholesterol in These Patients, With Fewer Major Vascular Events in Patients Taking VYTORIN ...